Baricitinib
- Generic Name
- Baricitinib
- Brand Names
- Olumiant
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N7O2S
- CAS Number
- 1187594-09-7
- Unique Ingredient Identifier
- ISP4442I3Y
- Background
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.
...
- Indication
In the US and Europe, baricitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. Baricitinib may be used as monotherapy or in combination with methotrexate or other DMARDs.
...
- Associated Conditions
- Alopecia Areata (AA), Coronavirus Disease 2019 (COVID‑19), Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
- Conditions
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Wes Ely
- Target Recruit Count
- 550
- Registration Number
- NCT06631287
- Locations
- 🇺🇸
Vanderbilt University Medical, Nashville, Tennessee, United States
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Target Recruit Count
- 150
- Registration Number
- NCT06573593
- Locations
- 🇨🇳
Second Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, China
Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06548802
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China
A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas
- Conditions
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 25
- Registration Number
- NCT06490757
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
- Conditions
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-08-23
- Target Recruit Count
- 150
- Registration Number
- NCT06475820
- Locations
- 🇷🇺
Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow, Samory-Mashela,1, Russian Federation
Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial
- Conditions
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 2000
- Registration Number
- NCT06381661
Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 30
- Registration Number
- NCT05950542
Baricitinib in Idiopathic Granulomatous Mastitis
- Conditions
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 20
- Registration Number
- NCT05852171
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Inflammation and Depression in People With HIV
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Emory University
- Target Recruit Count
- 60
- Registration Number
- NCT05849038
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Grady Memorial Hospital, Atlanta, Georgia, United States
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
- First Posted Date
- 2023-03-31
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT05792462
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.